Blogs

Thoughtful frustrated woman sitting at table near laptop

Filling the Tech Gap in Metastatic Breast Cancer Clinical Trials

According to the American Cancer Society (ACS), a woman living in the United States has a 1 in 8 chance of developing breast cancer, the second-leading cause of cancer death in women (behind only lung cancer). Despite advances in treatment, about 30% of women initially diagnosed with early-stage breast cancer will have a recurrence or experience metastatic disease.[i] Moreover, while…

Advanced Medical Technology

My Journey to AI-driven Clinical Trials

Throughout my two-decade career in the biopharmaceutical industry, my goal has been to make drug development more efficient while reducing costs, and to help the companies I have worked for increase revenue without compromising quality. In pursuing that goal, I have strived to embrace advanced technologies and to optimize organizational and operational structures. Now that I have joined Phesi, I…

b006

Pharma and Biotech are Waiting for 21st Century Clinical Trial Data Analytics Engines

As a repository of clinical trial information, few databases are as trusted – or as widely used – as www.clinicaltrials.gov. A service of the U.S. National Library of Medicine, clinicaltrials.gov aims to provide comprehensive information on privately and publicly funded clinical studies conducted around the world. Many drug developers mine the database to facilitate decisions on trial design, investigator recruitment,…

b007

Predicting Investigator Site Enrollment Performance: Separating Myth from Truth

Throughout my two-decade career in the biopharmaceutical industry, my goal has been to make drug development more efficient while reducing costs, and to help the companies I have worked for increase revenue without compromising quality. In pursuing that goal, I have strived to embrace advanced technologies and to optimize organizational and operational structures. Now that I have joined Phesi, I…

b009

Site, Investigator, or Investigator Site?

The life sciences industry is riddled with casually used terms, acronyms and phrases which are often used out of context or defined differently among companies or individuals. This becomes especially problematic when developing and designing clinical trials, as terms that are tossed around as ‘givens’ can be much more complex processes that may dictate success or failure of a clinical…

img

KOLs: An Endangered Buzzword

The term, “key opinion leader” (supported by its well-known acronym KOL) is one of the industry’s most common buzzwords, and for good reason. Physician KOLs have always influenced treatment guidelines and practice behaviors. They have traditionally exerted their influence through research and publication on drug safety and efficacy, which, while still valuable, must now share the stage with other important…

img

Smarter Trials Equal Faster Cures

In this era of “big data,” when we all have access to more data than ever before, it’s tempting to take a ‘DIY’ approach to clinical research. However, as search engines become increasingly sophisticated, many data sources commonly used to support clinical trial design lack such dynamism. For example, whereas many clinical trial planners rely on sources like clinicaltrials.gov, which…

blog-banner-1

Phesi Investigator Site Selection: an AI propelled platform

Much has been discussed about artificial intelligence in our industry. Coming to the core issues in clinical trial planning and execution, such as protocol design optimization, investigator site selection and the business process to put select investigator sites to work [namely site activation], we have yet to see hardly anything in the public space. In fact, our industry has been…

img

Using Actions, Not Words, to Reimagine Medicine

2018 has been a banner year for big pharma companies to re-focus on scientific innovation, with several companies making major investments in technology to advance the promise of personalized medicine. Take for example Roche’s acquisition (in February) of Flatiron Health – which provides almost real-time oncology patient data drawn from a network of cancer centers – for a whopping $1.9…

img

Site Effectiveness Index: A strategically important metric in clinical trial planning

The importance of site activation planning and implementation is a given among those who develop and manage clinical trials. However, some key considerations are often overlooked in the planning process, such as: How should we measure site activation? What is a good site activation plan? How do we define the relationship between site activation and other variables in clinical trial…